Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.52 |
| ▸ | DRD4 | P21917 | 4/20 | 0.50 |
| ▸ | DRD3 | P35462 | 2/20 | 0.50 |
| ▸ | USP5 | P45974 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 2/20 | 0.48 |
| ▸ | NPY1R | P25929 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CCR2 | P41597 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4949320 | 0.86 | DRD2 (0.64) | DRD2SMN1; SMN2CHRM4USP5HTR2C | |
| SCHEMBL7200383 | 0.85 | DRD2 (0.66) | DRD2SMN1; SMN2CHRM4DRD4DRD3 | |
| SCHEMBL7659138 | 0.80 | DRD2 (0.69) | DRD2SMN1; SMN2CHRM4USP5HTR2C | |
| SCHEMBL14067226 | 0.79 | DRD2 (0.72) | DRD2CHRM4USP5HTR2CCCR2 | |
| SCHEMBL8350724 | 0.78 | DRD2 (0.79) | DRD2CHRM4HTR2C | |
| SCHEMBL20240320 | 0.77 | DRD2 (0.78) | DRD2CHRM4HTR2CNPY1R | |
| SCHEMBL8479052 | 0.77 | DRD2 (0.78) | DRD2HTR2CNPY1R | |
| Hydrochloric Acid SCHEMBL30206729 | 0.76 | DRD2 (0.56) | DRD2CHRM4USP5HTR2CCCR2 | |
| SCHEMBL2637036 | 0.76 | DRD2 (0.59) | DRD2CHRM4USP5HTR2CCCR2 | |
| SCHEMBL14590572 | 0.76 | QDPR (0.61) | DRD2CHRM4USP5HTR2CCCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6596724-B2 | Used in promoting weight loss and treating eating disorders | BRISTOL-MYERS SQUIBB COMPANY | 2003-07-22 | — | — | US | disclosed |
| US-20020013323-A1 | Oxadiazole and thiadiazole derivatives of dihydropyridine NPY antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2002-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013323-A1 | Oxadiazole and thiadiazole derivatives of dihydropyridine NPY antagonists | NPY1R, NPY2R, NPY5R | DRD2 52/4885SMN1; SMN2 2598/4885CHRM4 1834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.